What happened with IBRX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
ImmunityBio, Inc.’s commercial business centers on ANKTIVA, a medicine that activates immune cells. Its U.S. approval covers use with BCG for adults whose bladder cancer has not responded to BCG and includes carcinoma in situ, with or without papillary tumors, without invading the bladder muscle.
U.S. ANKTIVA sales account for nearly all revenue. ImmunityBio supplies clinics and hospitals through specialty distributors and a specialty pharmacy. Government and private insurers’ coverage and reimbursement help fund treatment, so sales depend on physicians prescribing the combination and healthcare providers being able to obtain payment for it.
Because ANKTIVA must be given with BCG for this U.S. indication, BCG availability also limits treatment capacity. Merck’s TICE BCG is the only FDA-approved BCG strain available in the U.S. and remains in short supply. ImmunityBio has arranged an alternative supply with Serum Institute of India, but that product is available only in limited quantities through an expanded-access program, rather than general commercial approval. Other drug candidates remain in development and cannot generate product sales until approved and commercialized.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
ImmunityBio’s results hinge on ANKTIVA uptake against rivals including privately held Ferring’s ADSTRILADRIN, and on BCG availability, which its Serum Institute of India partnership seeks to improve.
CG Oncology is developing cretostimogene for the BCG-unresponsive bladder-cancer patients ImmunityBio already treats with ANKTIVA plus BCG. Its trial results are worth watching for a potential alternative in that same patient group; cretostimogene remains investigational.
enGene Therapeutics is developing detalimogene for the same high-risk, BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ that ImmunityBio treats with ANKTIVA plus BCG. Watch its single-drug treatment’s development progress: enGene plans to sell it independently in the U.S. if approved, but has no reported product sales.
Merck both competes with ImmunityBio through KEYTRUDA in BCG-unresponsive non-muscle-invasive bladder cancer and supplies TICE BCG, the companion treatment required for ANKTIVA’s U.S. regimen. Watch TICE BCG availability: ImmunityBio says Merck has been the sole U.S. BCG supplier since 2012, with rationing since 2019.
Johnson & Johnson’s INLEXZO competes with ImmunityBio’s ANKTIVA for patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Protara Therapeutics’ TARA-002 development puts another potential treatment into the non-muscle-invasive bladder-cancer market served by ImmunityBio’s ANKTIVA. Watch its bladder-cancer trial results rather than sales: Protara has generated no revenue since inception.
UroGen Pharma and ImmunityBio both depend on uptake of nonsurgical bladder-cancer drugs, but serve different patients: UroGen sells bladder-instilled Zusduri for recurrent low-grade, intermediate-risk disease, while ANKTIVA treats BCG-unresponsive carcinoma in situ. Zusduri uptake offers a view of adoption in urology practices, not a like-for-like measure of ANKTIVA demand.
Relmada Therapeutics’ lead candidate NDV-01 is in Phase 2 for non-muscle-invasive bladder cancer, making its development results relevant to the bladder-preserving treatment market served by ImmunityBio’s ANKTIVA. Watch NDV-01 trial updates, not commercial performance: Relmada has no approved products or revenue.
ImmunityBio relies on BeOne Medicines to supply tislelizumab for its confirmatory Phase 3 trial combining that drug with ANKTIVA in advanced or metastatic non-small-cell lung cancer resistant to checkpoint-inhibitor therapy. Watch the combination trial’s survival results, rather than BeOne’s blood-cancer drug sales, for evidence about ANKTIVA in this lung-cancer setting.
Fed Interest Rate Decision
The Fed’s decision on its benchmark interest rate matters to ImmunityBio because higher rates can raise interest expense and cash outflows on its $505 million note, which bears interest at Term SOFR plus 8%.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates across the economy can push up the interest rate on ImmunityBio’s note, increasing the cash it must pay toward interest and leaving less for operations and commercialization.
If it comes in below expectations
Lower rates across the economy can ease the interest rate on ImmunityBio’s note, reducing its interest cash outflows and leaving more cash available for operations and commercialization.
Merck & Co., Inc. earningsMRK
Merck supplies TICE BCG in the U.S., and ANKTIVA must be used with BCG; any supply update in Merck's report could show whether shortages are still limiting treatment.
Look for a specific update on TICE BCG supply or rationing. If supply improves, clinics may have an easier time obtaining the BCG required with ANKTIVA, so treatment volume is less constrained; if rationing continues, available treatment may remain limited even when patients and doctors want it. If the report says nothing about TICE BCG, Merck's other business results cannot establish whether supply has improved.
ImmunityBio, Inc. earningsThis company
ImmunityBio sells ANKTIVA for use with BCG, and this report will show how much clinic use is translating into product sales after discounts and rebates.
Read ANKTIVA product revenue alongside deductions such as rebates and discounts. If revenue grows faster than those deductions, more treatment demand is showing up as sales ImmunityBio can recognize; if revenue stalls or deductions grow faster, payer concessions and other adjustments are eating into sales. Then check BCG supply: if it remains constrained, weak sales may reflect fewer available treatments, not weak patient demand.
BeOne Medicines Ltd. earningsONC
If BeOne updates survival results from its tislelizumab-and-ANKTIVA lung-cancer trial, readers can assess whether the combination has evidence behind it in this setting.
If BeOne reports survival results from the combination trial, look for evidence that patients lived longer. A benefit would support further development of ANKTIVA with tislelizumab in this lung-cancer setting, but would not show ANKTIVA's contribution on its own; a weak result would weaken the case for this development path. BeOne's sales of other drugs cannot answer the question if the report gives no trial update.
enGene Therapeutics Inc. earningsENGN
If enGene Therapeutics reports progress on detalimogene for the same high-risk bladder-cancer group, its results will show how far a potential alternative to ImmunityBio's ANKTIVA has advanced.
Look for trial or development updates on detalimogene in high-risk, BCG-unresponsive patients with carcinoma in situ. Clear progress would make this potential alternative for the same patient group more credible, but it is not an approved product and is not yet taking sales from ANKTIVA; setbacks would reduce the evidence that it may become a competitor.
